# Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers

> **NCT04616105** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** REGN6490
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04616105
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-18
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-05-28
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2021-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616105, "Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04616105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*